{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:48:36Z","timestamp":1769431716912,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-021-04851-z","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T08:10:51Z","timestamp":1625472651000},"page":"651-657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Epidemiologie, Patientenlebensqualit\u00e4t und Behandlungskosten der Hidradenitis suppurativa\/Acne inversa","Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa\/acne inversa"],"prefix":"10.1007","volume":"72","author":[{"given":"N.","family":"Kirsten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Frings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. D.","family":"Nikolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Presser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"4851_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1203475417745826","volume":"22","author":"A Alavi","year":"2018","unstructured":"Alavi\u00a0A, Farzanfar\u00a0D, Lee\u00a0RK et\u00a0al (2018) The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J\u00a0Cutan Med Surg 22:166\u2013174","journal-title":"J Cutan Med Surg"},{"key":"4851_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.17151","volume":"180","author":"M Argyropoulou","year":"2019","unstructured":"Argyropoulou\u00a0M, Kanni\u00a0T, Kyprianou\u00a0M et al (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a\u00a0retrospective analysis of a\u00a0real-world cohort. Br J Dermatol 180:1161\u20131168","journal-title":"Br J Dermatol"},{"key":"4851_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15280","volume":"176","author":"F Balieva","year":"2017","unstructured":"Balieva\u00a0F, Kupfer\u00a0J, Lien\u00a0L et\u00a0al (2017) The burden of common skin diseases assessed with the EQ5D: a\u00a0European multicentre study in 13\u00a0countries. Br J Dermatol 176:1170\u20131178","journal-title":"Br J Dermatol"},{"key":"4851_CR4","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.3390\/ijerph18116131","volume":"18","author":"PV Chernyshov","year":"2021","unstructured":"Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al (2021) Quality of life in hidradenitis suppurativa. An update. Int J Environ Res Public Health 18:6131","journal-title":"Int J Environ Res Public Health"},{"key":"4851_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaad.2013.06.042","volume":"69","author":"I Cosmatos","year":"2013","unstructured":"Cosmatos\u00a0I, Matcho\u00a0A, Weinstein\u00a0R et\u00a0al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J\u00a0Am Acad Dermatol 69:819","journal-title":"J Am Acad Dermatol"},{"key":"4851_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000501905","volume":"236","author":"C Cuenca-Barrales","year":"2020","unstructured":"Cuenca-Barrales\u00a0C, Molina-Leyva\u00a0A (2020) Risk factors of sexual dysfunction in patients with hidradenitis suppurativa: a cross-sectional study. Dermatology 236:37\u201345","journal-title":"Dermatology"},{"key":"4851_CR7","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1111\/ijd.15037","volume":"60","author":"JM Fernandez","year":"2021","unstructured":"Fernandez\u00a0JM, Rizvi\u00a0OH, Marr\u00a0KD et\u00a0al (2021) Itch and pain by lesion morphology in hidradenitis suppurativa patients. Int J Dermatol 60:e56\u2013e59","journal-title":"Int J Dermatol"},{"key":"4851_CR8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1684\/ejd.2019.3552","volume":"29","author":"VG Frings","year":"2019","unstructured":"Frings\u00a0VG, Bauer\u00a0B, Gloditzsch\u00a0M et\u00a0al (2019) Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 29:294\u2013301","journal-title":"Eur J Dermatol"},{"issue":"12","key":"4851_CR9","first-page":"4046","volume":"9","author":"S Garcovich","year":"2020","unstructured":"Garcovich S, Muratori S, Moltrasio C et al (2020) Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J\u00a0Clin Med 9(12):4046","journal-title":"J\u00a0Clin Med"},{"key":"4851_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg\u00a0A, Kirby\u00a0JS, Lavian\u00a0J et al (2017) Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 153:760\u2013764","journal-title":"JAMA Dermatol"},{"key":"4851_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2018.02.053","volume":"79","author":"A Garg","year":"2018","unstructured":"Garg\u00a0A, Papagermanos\u00a0V, Midura\u00a0M et al (2018) Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J\u00a0Am Acad Dermatol 79:495\u2013500.e1","journal-title":"J Am Acad Dermatol"},{"key":"4851_CR12","first-page":"1","volume":"9","author":"K Gaspar","year":"2021","unstructured":"Gaspar K, Hunor Gergely L, Jenei B et al (2021) Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a\u00a0cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res 9:1\u201310","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4851_CR13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/bjd.14975","volume":"176","author":"IC Janse","year":"2017","unstructured":"Janse\u00a0IC, Deckers\u00a0IE, Van Der Maten\u00a0AD et al (2017) Sexual health and quality of life are impaired in hidradenitis suppurativa: a\u00a0multicentre cross-sectional study. Br J Dermatol 176:1042\u20131047","journal-title":"Br J Dermatol"},{"key":"4851_CR14","doi-asserted-by":"crossref","unstructured":"Jfri AND, O\u2019brien E, Gulliver W, Nikolakis G, Zouboulis CC (2021) Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol :e211677","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"4851_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2340\/00015555-2967","volume":"98","author":"K Kaaz","year":"2018","unstructured":"Kaaz\u00a0K, Szepietowski\u00a0JC, Matusiak\u00a0L (2018) Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol 98:757\u2013761","journal-title":"Acta Derm Venereol"},{"key":"4851_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.det.2015.08.005","volume":"34","author":"I Karagiannidis","year":"2016","unstructured":"Karagiannidis\u00a0I, Nikolakis\u00a0G, Zouboulis\u00a0CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45\u201349","journal-title":"Dermatol Clin"},{"key":"4851_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","volume":"150","author":"JS Kirby","year":"2014","unstructured":"Kirby\u00a0JS, Miller\u00a0JJ, Adams\u00a0DR et\u00a0al (2014) Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol 150:937\u2013944","journal-title":"JAMA Dermatol"},{"key":"4851_CR18","volume-title":"HS-QoL: Disease specific instrument to assess quality of life in patients with hidradenitis suppurativa","author":"NOM Kirsten","year":"2019","unstructured":"Kirsten\u00a0NOM, Bechara\u00a0F et al (2019) HS-QoL: Disease specific instrument to assess quality of life in patients with hidradenitis suppurativa. Oral presentation; 8th Conference of the European Hidradenitis Suppurativa Foundation, Wroclaw, 02.2019"},{"key":"4851_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.15940","volume":"34","author":"N Kirsten","year":"2020","unstructured":"Kirsten\u00a0N, Petersen\u00a0J, Hagenstrom\u00a0K et\u00a0al (2020) Epidemiology of hidradenitis suppurativa in Germany\u2014an observational cohort study based on a\u00a0multisource approach. J\u00a0Eur Acad Dermatol Venereol 34:174\u2013179","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4851_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00403-020-02065-2","volume":"313","author":"N Kirsten","year":"2021","unstructured":"Kirsten\u00a0N, Zander\u00a0N, Augustin\u00a0M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313:95\u201399","journal-title":"Arch Dermatol Res"},{"key":"4851_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaad.2011.10.024","volume":"67","author":"A Kurek","year":"2012","unstructured":"Kurek\u00a0A, Peters\u00a0EM, Chanwangpong\u00a0A et\u00a0al (2012) Profound disturbances of sexual health in patients with acne inversa. J\u00a0Am Acad Dermatol 67:422\u2013428, 428 e421","journal-title":"J Am Acad Dermatol"},{"key":"4851_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712.x","volume":"17","author":"H Kurzen","year":"2008","unstructured":"Kurzen\u00a0H, Kurokawa\u00a0I, Jemec\u00a0GB et\u00a0al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455\u2013456 (discussion 457\u2013472)","journal-title":"Exp Dermatol"},{"key":"4851_CR23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/pde.14326","volume":"37","author":"M Lam","year":"2020","unstructured":"Lam\u00a0M, Lai\u00a0C, Almuhanna\u00a0N et al (2020) Hidradenitis suppurativa and down syndrome: a systematic review and meta-analysis. Pediatr Dermatol 37:1044\u20131050","journal-title":"Pediatr Dermatol"},{"key":"4851_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1525-1470.2011.01425.x","volume":"29","author":"T Lazic","year":"2012","unstructured":"Lazic\u00a0T, Li\u00a0Q, Frank\u00a0M et al (2012) Extending the phenotypic spectrum of keratitis-ichthyosis-deafness syndrome: report of a\u00a0patient with GJB2 (G12R) Connexin 26 mutation and unusual clinical findings. Pediatr Dermatol 29:349\u2013357","journal-title":"Pediatr Dermatol"},{"key":"4851_CR25","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jdv.15071","volume":"32","author":"JH Lee","year":"2018","unstructured":"Lee\u00a0JH, Kwon\u00a0HS, Jung\u00a0HM et al (2018) Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a\u00a0nationwide population-based study. J\u00a0Eur Acad Dermatol Venereol 32:1784\u20131790","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4851_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1440-0960.1997.tb01700.x","volume":"38","author":"M Li","year":"1997","unstructured":"Li\u00a0M, Hunt\u00a0MJ, Commens\u00a0CA (1997) Hidradenitis suppurativa, Dowling Degos disease and perianal squamous cell carcinoma. Australas J Dermatol 38:209\u2013211","journal-title":"Australas J Dermatol"},{"key":"4851_CR27","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/MD.0000000000000187","volume":"93","author":"AV Marzano","year":"2014","unstructured":"Marzano\u00a0AV, Ceccherini\u00a0I, Gattorno\u00a0M et\u00a0al (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93:e187","journal-title":"Medicine"},{"key":"4851_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","volume":"62","author":"L Matusiak","year":"2010","unstructured":"Matusiak\u00a0L, Bieniek\u00a0A, Szepietowski\u00a0JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J\u00a0Am Acad Dermatol 62:706\u2013708, 708 e701","journal-title":"J Am Acad Dermatol"},{"key":"4851_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2815","volume":"98","author":"L Matusiak","year":"2018","unstructured":"Matusiak\u00a0L, Szczech\u00a0J, Kaaz\u00a0K et\u00a0al (2018) Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 98:191\u2013194","journal-title":"Acta Derm Venereol"},{"key":"4851_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/1203475417736281","volume":"22","author":"C Mclellan","year":"2018","unstructured":"Mclellan\u00a0C, Sisic\u00a0M, Oon\u00a0HH et al (2018) Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J\u00a0Cutan Med Surg 22:142\u2013146","journal-title":"J Cutan Med Surg"},{"key":"4851_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000502139","volume":"236","author":"A Molina-Leyva","year":"2020","unstructured":"Molina-Leyva\u00a0A, Cuenca-Barrales\u00a0C (2020) Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology 236:59\u201365","journal-title":"Dermatology"},{"key":"4851_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","volume":"42","author":"MT Nguyen","year":"2012","unstructured":"Nguyen\u00a0MT, Borchers\u00a0A, Selmi\u00a0C et\u00a0al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254\u2013265","journal-title":"Semin Arthritis Rheum"},{"key":"4851_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjd.18656","volume":"182","author":"RM Nielsen","year":"2020","unstructured":"Nielsen\u00a0RM, Lindso Andersen\u00a0P, Sigsgaard\u00a0V et\u00a0al (2020) Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 182:166\u2013174","journal-title":"Br J Dermatol"},{"key":"4851_CR34","first-page":"1","volume":"9","author":"G Nikolakis","year":"2020","unstructured":"Nikolakis\u00a0G, Kaleta\u00a0KP, Vaiopoulos\u00a0AG et\u00a0al (2020) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: Different faces of the same disease? A\u00a0systematic review. Dermatology 9:1\u201325","journal-title":"Dermatology"},{"key":"4851_CR35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00105-020-04679-z","volume":"71","author":"G Nikolakis","year":"2020","unstructured":"Nikolakis\u00a0G, Karagiannidis\u00a0I, Vaiopoulos\u00a0AG et\u00a0al (2020) Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 71:762\u2013771","journal-title":"Hautarzt"},{"key":"4851_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.12688\/f1000research.52100.2","volume":"10","author":"GKK Nikolakis","year":"2021","unstructured":"Nikolakis GKK, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC (2021) Successful application of secukinumab for the treatment of PsAPSASH syndrome, an alternative phenotype of syndromic hidradenitis suppurativa. F1000 Research 10:381","journal-title":"F1000 Research"},{"key":"4851_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1468-3083.2012.04468.x","volume":"27","author":"AJ Onderdijk","year":"2013","unstructured":"Onderdijk\u00a0AJ, Van Der Zee\u00a0HH, Esmann\u00a0S et\u00a0al (2013) Depression in patients with hidradenitis suppurativa. J\u00a0Eur Acad Dermatol Venereol 27:473\u2013478","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4851_CR38","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/ajd.13110","volume":"61","author":"K Phan","year":"2020","unstructured":"Phan\u00a0K, Charlton\u00a0O, Smith\u00a0SD (2020) Hidradenitis suppurativa and polycystic ovarian syndrome: systematic review and meta-analysis. Australas J Dermatol 61:e28\u2013e33","journal-title":"Australas J Dermatol"},{"key":"4851_CR39","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter\u00a0T, Nestler-Parr\u00a0S, Babela\u00a0R et al (2015) Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR rare disease special interest group. Value Health 18:906\u2013914","journal-title":"Value Health"},{"key":"4851_CR40","doi-asserted-by":"crossref","first-page":"adv00319","DOI":"10.2340\/00015555-3477","volume":"100","author":"F Sampogna","year":"2020","unstructured":"Sampogna\u00a0F, Fania\u00a0L, Mastroeni\u00a0S et\u00a0al (2020) Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol 100:adv319","journal-title":"Acta Derm Venereol"},{"key":"4851_CR41","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte\u00a0DM, Boer\u00a0J, Stratigos\u00a0A et\u00a0al (2015) Diagnostic delay in hidradenitis suppurativa is a\u00a0global problem. Br J Dermatol 173:1546\u20131549","journal-title":"Br J Dermatol"},{"key":"4851_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjd.16998","volume":"180","author":"P Theut Riis","year":"2019","unstructured":"Theut Riis\u00a0P, Pedersen\u00a0OB, Sigsgaard\u00a0V et al (2019) Prevalence of patients with self-reported hidradenitis suppurativa in a\u00a0cohort of Danish blood donors: a\u00a0cross-sectional study. Br J Dermatol 180:774\u2013781","journal-title":"Br J Dermatol"},{"key":"4851_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","volume":"138","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius\u00a0L, Cohen\u00a0AD, Gislason\u00a0GH et\u00a0al (2018) Increased suicide risk in patients with hidradenitis suppurativa. J\u00a0Invest Dermatol 138:52\u201357","journal-title":"J Invest Dermatol"},{"key":"4851_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos\u00a0T, Yang\u00a0H, Mu\u00a0F et\u00a0al (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147\u2013154","journal-title":"Br J Dermatol"},{"key":"4851_CR45","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/jdv.16520","volume":"34","author":"AG Vaiopoulos","year":"2020","unstructured":"Vaiopoulos\u00a0AG, Nikolakis\u00a0G, Zouboulis\u00a0CC (2020) Hidradenitis suppurativa in paediatric patients: a\u00a0retrospective monocentric study in Germany and review of the literature. J\u00a0Eur Acad Dermatol Venereol 34:2140\u20132146","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4851_CR46","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2340\/00015555-2176","volume":"95","author":"N Vlassova","year":"2015","unstructured":"Vlassova\u00a0N, Kuhn\u00a0D, Okoye\u00a0GA (2015) Hidradenitis suppurativa disproportionately affects African Americans: a\u00a0single-center retrospective analysis. Acta Derm Venereol 95:990\u2013991","journal-title":"Acta Derm Venereol"},{"key":"4851_CR47","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/jdv.16255","volume":"34","author":"K Wlodarek","year":"2020","unstructured":"Wlodarek\u00a0K, Glowaczewska\u00a0A, Matusiak\u00a0L et\u00a0al (2020) Psychosocial burden of hidradenitis suppurativa patients\u2019 partners. J\u00a0Eur Acad Dermatol Venereol 34:1822\u20131827","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4851_CR48","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bjd.19798","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC (2021) Pain Index: a\u00a0new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203\u20131204","journal-title":"Br J Dermatol"},{"key":"4851_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/bjd.17396","volume":"181","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis\u00a0CC (2019) The socioeconomic burden of hidradenitis suppurativa\/acne inversa. Br J Dermatol 181:7\u20138","journal-title":"Br J Dermatol"},{"issue":"7","key":"4851_CR50","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jdv.17306","volume":"35","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J\u00a0Eur Acad Dermatol Venereol 35(7):1420\u20131421","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"4851_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, Del Marmol\u00a0V, Mrowietz\u00a0U et\u00a0al (2015) Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184\u2013190","journal-title":"Dermatology"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04851-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04851-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04851-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T17:10:25Z","timestamp":1699204225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04851-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4851"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04851-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"26 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"V.\u00a0Frings und G.D.\u00a0Nikolakis geben an, dass kein Interessenkonflikt besteht. D.\u00a0Presser und M.\u00a0Goebeler waren Pr\u00fcfarzte in klinischen Studien zur AI\/HS der Firmen UCB und Novartis. C.C.\u00a0Zouboulis hat Berater- und Vortragshonorare von Idorsia, Incyte, InflaRx, Janssen, Novartis, Regeneron und UCB erhalten, die nicht mit diesem Manuskript in Verbindung stehen. Seine Abteilung erhielt Honorare von AbbVie, InflaRx, Novartis und UCB f\u00fcr seine Teilnahme an klinischen Studien. N.\u00a0Kirsten hat Berater- und Vortragshonorare von AbbVie, Eli Lilly, Janssen, Novartis, UCB, Streamedup, Uluru erhalten und war als Pr\u00fcf\u00e4rztin an klinischen Studien zur AI\/HS der Firmen UCB, AbbVie, Novartis beteiligt. M.\u00a0Augustin hat Berater- und Vortragshonorare von AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO, Medac, Merck, MSD, Novartis, Pfizer, UCB und XenoPort erhalten und war an klinischen Studien der Firmen AbbVie, Novartis, UCB zur AI\/HS als Pr\u00fcfarzt beteiligt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}